Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTRA: Rivastigmine Patch in Alzheimer's Disease
NCT00622713Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoint: Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study. Started Jan 2008; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00622713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622713.